CD8A and COVID-19: In contrast, in a small study of multiple sclerosis patients on active monotherapy with anti-CD20 monoclonal antibodies, all patients developed a CD4+ and CD8+ T cell response to vaccination with COVID-19 mRNA-based vaccines, which suggests that, in CLL, the underlying hematological disease might also play a role [60].